{"id":55371,"date":"2023-03-30T17:07:31","date_gmt":"2023-03-30T15:07:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"modified":"2023-03-30T17:07:31","modified_gmt":"2023-03-30T15:07:31","slug":"cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","title":{"rendered":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ADPD23<\/a>—Cognito Therapeutics,<\/a> today announced neuroimaging results evaluating the effects of the company\u2019s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD\/PD\u2122 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March 28\u2013April 1, 2023 in Gothenburg, Sweden.\n<\/p>\n

<\/a><\/p>\n

\nNeuroimaging data was prospectively collected in the OVERTURE clinical trial (NCT03556280) along with safety, tolerability, and efficacy of Cognito Therapeutics\u2019 medical device in participants with Alzheimer\u2019s disease. 76 participants were randomized 2:1 to receive daily, one-hour, EEG-assessed, proprietary non-invasive neuromodulation (active arm, n=46) or sham (placebo arm, n=28) stimulation over a 6-month period. AD brain pathological changes were evaluated by neuroimaging methods, including volumetric MRI and [18]florbetapir PET.\n<\/p>\n

\nResults<\/b>\n<\/p>\n

\nA significant reduction in whole brain volume loss was observed, which correlated with reduced lateral ventricle expansion, in subjects in the active compared to the sham group. The active group also showed a significantly reduced loss in white matter volume, occipital lobe volume and cortical thickness. Volumetric changes showed correlations between brain regions and clinical outcomes, prominently between occipital lobe and activity of daily living (ADCS-ADL). Although neither the active nor the sham arm participants showed a significant difference in amyloid plaque load, Cognito\u2019s proprietary neuromodulation was effective in both amyloid positive and negative subjects, including maintaining cognitive and functional efficacy outcomes.\n<\/p>\n

\n“The results presented at AD\/PD 2023 from our Phase 2 OVERTURE clinical trial show that daily at-home use of our medical device decreases brain atrophy in Alzheimer\u2019s patients,\u201d said Brent Vaughan, CEO, Cognito Therapeutics. \u201cOur innovative approach, utilizing non-invasive neuromodulation and neuroimaging methods, has yielded impressive results, including a significant reduction in whole brain MRI volume loss and potentially improved clinical outcomes. We are particularly encouraged by the correlations between reduced brain volume loss and clinical outcomes, as well as the impact of our therapy on both amyloid positive and negative patients. These findings indicate a potential breakthrough in Alzheimer’s research and provide hope for the millions of individuals and families affected by this disease. We remain committed to advancing our research and development efforts in bringing our innovative neurotechnology device to patients.”\n<\/p>\n

\nAbout Cognito Therapeutics<\/b>\n<\/p>\n

\nCognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company\u2019s lead therapy is currently in a pivotal study in Alzheimer\u2019s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com<\/a>. Follow us on Twitter at @cognitotx.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
Kimberly Ha
\n
KKH Advisors
\n
917-291-5744
\n
kimberly.ha@kkhadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ADPD23—Cognito Therapeutics, today announced neuroimaging results evaluating the effects of the company\u2019s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD\/PD\u2122 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March 28\u2013April … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55371","6":"format-standard","7":"category-industry"},"yoast_head":"\nCognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ADPD23—Cognito Therapeutics, today announced neuroimaging results evaluating the effects of the company\u2019s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD\/PD\u2122 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March 28\u2013April ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T15:07:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023\",\"datePublished\":\"2023-03-30T15:07:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"},\"wordCount\":478,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005621\\\/en\\\/1752137\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\",\"name\":\"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005621\\\/en\\\/1752137\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg\",\"datePublished\":\"2023-03-30T15:07:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005621\\\/en\\\/1752137\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005621\\\/en\\\/1752137\\\/21\\\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","og_locale":"en_US","og_type":"article","og_title":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ADPD23—Cognito Therapeutics, today announced neuroimaging results evaluating the effects of the company\u2019s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD\/PD\u2122 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March 28\u2013April ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-30T15:07:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023","datePublished":"2023-03-30T15:07:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"wordCount":478,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","url":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","name":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg","datePublished":"2023-03-30T15:07:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005621\/en\/1752137\/21\/full_-_gardient_-_dark_text%402x_%284%29_%284%29_%281%29_%287%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cognito-therapeutics-announces-gamma-frequency-sensory-stimulation-decreases-brain-atrophy-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer\u2019s Disease at AD\/PD 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55371"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55371\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}